OncLive® On Air

S13 Ep26: ASCO 2025 Plenary — MATTERHORN


Listen Later

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago.

In this episode, OncLive On Air® partnered with Two Onc Docs to bring a discussion of key data from the phase 3 MATTERHORN trial (NCT04592913), which were presented at the 2025 ASCO Annual Meeting. MATTERHORN was a randomized, double-blind, multinational study evaluating the addition of durvalumab (Imfinzi) to FLOT (5-fluorouracil, leucovorin, oxaliplatin, and docetaxel) in patients with previously untreated, resectable gastric or gastroesophageal junction adenocarcinoma.

In the MATTERHORN trial, 948 patients were randomly assigned 1:1 to receive either durvalumab or placebo in combination with perioperative FLOT, followed by 10 cycles of durvalumab or placebo as adjuvant therapy. The primary end point was event-free survival (EFS); secondary end points included overall survival (OS) and pathological complete response (pCR).

The trial met its primary end point. Durvalumab plus FLOT (n = 474) significantly improved EFS vs placebo plus FLOT (n = 474; HR, 0.71; 95% CI, 0.58-0.86; P < .001), representing a 29% reduction in risk of progression, recurrence, or death. The interim OS analysis showed a nonsignificant trend favoring durvalumab (HR, 0.78; 95% CI, 0.62-0.97; P = .025). The pCR rate was 19% (95% CI, 15.75%-23.04%) with durvalumab vs 7.2% (95% CI, 5.02%-9.88%) with placebo.

Toxicity profiles were comparable between the 2 groups, though immune-related adverse effects were more frequent with durvalumab. Importantly, the addition of durvalumab did not delay surgery or initiation of adjuvant therapy.

Although the MATTERHORN regimen is not yet FDA approved or included in the National Comprehensive Cancer Network guidelines, this trial demonstrates a promising EFS benefit and potential practice-changing implications, pending mature OS data and further molecular subgroup analyses, according to Armstrong and Tawagi.
...more
View all episodesView all episodes
Download on the App Store

OncLive® On AirBy OncLive® On Air

  • 4.2
  • 4.2
  • 4.2
  • 4.2
  • 4.2

4.2

21 ratings


More shows like OncLive® On Air

View all
Wait Wait... Don't Tell Me! by NPR

Wait Wait... Don't Tell Me!

38,689 Listeners

Marketplace Morning Report by Marketplace

Marketplace Morning Report

902 Listeners

Marketplace by Marketplace

Marketplace

8,659 Listeners

Research To Practice | Oncology Videos by Dr Neil Love

Research To Practice | Oncology Videos

113 Listeners

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast by PVI, PeerView Institute for Medical Education

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

10 Listeners

JAMA Clinical Reviews by JAMA Network

JAMA Clinical Reviews

493 Listeners

ASCO Daily News by American Society of Clinical Oncology (ASCO)

ASCO Daily News

58 Listeners

The Curbsiders Internal Medicine Podcast by The Curbsiders Internal Medicine Podcast

The Curbsiders Internal Medicine Podcast

3,332 Listeners

OncoPharm by John Bossaer

OncoPharm

185 Listeners

ASCO Guidelines by American Society of Clinical Oncology (ASCO)

ASCO Guidelines

43 Listeners

Lung Cancer Considered by IASLC

Lung Cancer Considered

27 Listeners

Oncology Today with Dr Neil Love by Dr. Neil Love

Oncology Today with Dr Neil Love

56 Listeners

Two Onc Docs by Sam and Karine

Two Onc Docs

169 Listeners

Oncology Brothers: Practice-Changing Cancer Discussions by Oncology Brothers

Oncology Brothers: Practice-Changing Cancer Discussions

39 Listeners

NEJM AI Grand Rounds by NEJM Group

NEJM AI Grand Rounds

54 Listeners